ReviewClinical reviews in allergy & immunology2002
An overview of chronic urticaria.
Review in Clinical reviews in allergy & immunology, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Cluster Analysis of Clinical Remission and Relapse Patterns in Chronic Urticaria: Results from the PREDICT-CU Study.Dermatology and therapy · 2025Article
- Clinical review: The suggested management pathway for urticaria in primary care.Clinical and translational allergy · 2022Review
- Clinical Remission of Chronic Spontaneous Urticaria (CSU): A Targeted Literature Review.Dermatology and therapy · 2022Review
- Use of biologics in chronic spontaneous urticaria - beyond omalizumab therapy?Allergologie select · 2021Review
- Chronic urticaria in most patients is poorly controlled. Results of the development, validation, and real life application of the arabic urticaria control test.Saudi medical journal · 2017Observational
- The burden of chronic spontaneous urticaria is substantial: Real-world evidence from ASSURE-CSU.Allergy · 2017Article
- Cost Utility of Omalizumab Compared with Standard of Care for the Treatment of Chronic Spontaneous Urticaria.PharmacoEconomics · 2016Article
- Chronic urticaria.Indian journal of dermatology · 2011Article
- Position statement for the use of omalizumab in the management of chronic spontaneous urticaria in Indian patients.Indian dermatology online journalReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acknowledging urticaria as a symptom of mast cell degranulation is stressed. The biology of the mast cell, and the recognized immunologic and non-immunologic mast cell secretagogues are individually discussed along with mechanisms of activation and mediators released. The major, preformed mediator histamine in the skin produces a prototypic, short-lived urticaria, however, the clinical spectrum and pattern of "hives" indicate that other mediators contribute to the polymorphism and variable behavior of this symptom. The clinical assessment is almost exclusively restricted to the history and physical examination. Features to review and examine are presented. The cause of "acute" urticaria is identifiable (by history) in the majority of patients, and except for hives that accompany an anaphylactic reaction, these patients rarely present to the physician for care. The persistent, or "chronic" hiver whose history cannot elicit a cause, is rarely triggered by an individual trigger, despite extensive professional evaluation. Evidence to support changing the chronological, "acute" and "chronic" classification of urticaria to "identifiable" and "non-identifiable" triggered urticaria is discussed, as is the futility of extensive, costly laboratory work-ups. The natural history of urticaria reveals that management should be directed toward allowing the patient to maintain an acceptable quality of life (with or without some urticaria), until the episode resolves.
Indexed as
Identifiers
12221861What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.